Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Accumulated Depreciation (2021 - 2024)

Kezar Life Sciences (KZR) has disclosed Accumulated Depreciation for 4 consecutive years, with $6.2 million as the latest value for Q3 2024.

  • For Q3 2024, Accumulated Depreciation rose 20.64% year-over-year to $6.2 million; the TTM value through Sep 2024 reached $6.2 million, up 20.64%, while the annual FY2023 figure was $5.4 million, 17.77% up from the prior year.
  • Accumulated Depreciation hit $6.2 million in Q3 2024 for Kezar Life Sciences, up from $5.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $6.2 million in Q3 2024 and bottomed at $3.0 million in Q1 2021.
  • Average Accumulated Depreciation over 4 years is $4.6 million, with a median of $4.6 million recorded in 2022.
  • Year-over-year, Accumulated Depreciation soared 31.25% in 2022 and then grew 16.42% in 2023.
  • Kezar Life Sciences' Accumulated Depreciation stood at $3.7 million in 2021, then rose by 26.01% to $4.6 million in 2022, then increased by 17.77% to $5.4 million in 2023, then rose by 14.41% to $6.2 million in 2024.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $6.2 million, $5.9 million, and $5.7 million for Q3 2024, Q2 2024, and Q1 2024 respectively.